

Quality-Data Code Submission Error Report 2008 Physician Quality Reporting Initiative Report Date: 04/03/2009

This summary is provided to assist eligible professionals and their staff in interpreting the Quality-Data Code Submission Error Report by Measure. Please note that this report is based on the number of valid quality-data codes (QDCs) submitted by measure and reasons why a submission is considered invalid. This report does not include the number of claims for which an expected QDC was not submitted on an eligible claim.

The following PQRI analytical changes were implemented for this report:

- Diagnoses from both the line item and base level of the claim were utilized
- Split claims were rejoined based on common data elements (TIN, NPI, beneficiary, and date of service)
- ASC facility claims indicated by a type of service "F" were excluded. Claims with a place of service "81" were not excluded for this report.

Column Definitions:

- Total QDCs Reported - Number of QDC submissions for a measure whether or not the QDC submission was valid and appropriate for a measure.
- Total Valid QDCs Reported - Number of valid and appropriate QDC submissions for a measure.
- Patient Age Mismatch - Patient did not meet age requirements for the measure.
- Patient Gender Mismatch - Patient did not meet gender requirement for the measure.
- Incorrect HCPCS - Incorrect HCPCS code for the measure - Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis - Incorrect diagnosis code on claim - Patient claim did not meet denominator eligibility per measure specifications.
- Incorrect Diagnosis and HCPCS - Combination of incorrect HCPCS code and incorrect diagnosis code on claim - Patient claim did not meet denominator eligibility per measure specifications.
- Only QDC on Claim - Patient claim missing a qualifying denominator code (all line items contained only QDCs).
- Only QDC and Incorrect Diagnosis - Combination of missing qualifying denominator code and qualifying diagnosis code on the claim.
- Resubmitted QDCs - Submissions invalid due to resubmission of claims simply for the purpose of adding QDCs.
- Unattributed/No NPI - Submissions where the rendering NPI was missing.

How to Read the Quality-Data Code Submission Error Report by Measure:

Using Measure #47-Advance Care Plan as an example, we find the following information as we read across each column: 353,893 QDC submissions were received for this measure, 287,122 of which were considered valid. Therefore, the Valid Submission Rate is 81.13%. The rest of the columns explain reasons for invalid submissions for measure #47. We see that 16,999 (4.80%) submissions did not match the measure's age parameters; there is no gender parameter for this measure; 30,853 (8.72%) submissions were for patient encounters that are not listed in the denominator; this measure applies to all Medicare Part B beneficiaries regardless of diagnosis; 20,815 (5.88%) submissions showed only the numerator component (QDCs) on the claim and the denominator component (HCPCS) were not on the claim nor on any other related claim for the same beneficiary, date-of-service, NPI/TIN. There were no submissions with a combination of QDC-only and diagnosis mismatch and no QDC resubmissions for this measure; 398 (0.11%) submissions lacked an NPI in the rendering provider ID field on the claim.

Analysis Findings Include:

- The percent valid QDC submission increased 11.1% as a result of the analytic improvements (57.2% valid without analytic changes and 68.3% valid with the changes).
- Decreases as a result of analytic improvements were observed for the following types of errors:
 - Incorrect HCPCS decreased from 15.6 % to 12.2%
 - Incorrect DX decreased from 14.9% to 11.11%
 - Both Incorrect HCPCS and DX decreased from 2.3% to 0.96%
 - Only QDC on Claim decreased from 6.4% to 2.57%
 - Incorrect DX and Only QDC on Claim decreased from 1.5% to 0.92%
- The measures with the highest percentage of valid QDCs codes submitted were #105 Three-dimensional Radiotherapy for Patients with Prostate Cancer (95.66%), #59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia (94.77%), #102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients (94.59%), #58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia (94.53%), #125 HIT - Adoption/Use of e-Prescribing (94.53%), #131 Assessment Prior to Initiation of Patient Treatment (94.10%), #56 Vital Signs for Community-Acquired Bacterial Pneumonia (93.67%), #124 HIT - Adoption/Use of EHRs (92.71%), #81 Plan of Care for Inadequate Hemodialysis (92.22%) and #80 Plan of Care for ESRD Patients with Anemia (92.16%).
- Four of the Otitis measures (#94, #95, #96, #97 and #98), the Upper Respiratory Infection (URI) measure (#66) and the Pharyngitis measure (#66) had no valid QDCs submitted.
- Measure #82 Plan of Care for Inadequate Peritoneal Dialysis had the highest percentage of claims with QDCs only (86.53%).
- Measure #71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer had the highest percentage of resubmitted QDCs (0.17%).
- The rate of diagnosis errors was highest for measure #94 OME: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility (84.23%).
- The rate of HCPCS errors was highest for measure #20 Timing of Antibiotic Prophylaxis - Ordering Physician (84.40%).

Quality Data Code Submission Error Report by Measure
 Report Includes Data from the January 2008 through September 2008 TAP File

Measure	QDC Submission Attempts			Denominator Mismatch ^e														Resubmitted QDCs ^f		Unattributed (No NPI) ^g		
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC						
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%			
Advance Care Plan																						
#47 Advance Care Plan	353,893	287,122	81.13%	16,999	4.80%	0	0.00%	30,853	8.72%	0	0.00%	0	0.00%	20,815	5.88%	0	0.00%	0	0.00%	398	0.11%	
Arthritis-Osteoarthritis																						
#109 Patients with OA with an Assessment of Pain and Function	43,359	38,524	88.85%	0	0.00%	0	0.00%	1,256	2.90%	3,090	7.13%	148	0.34%	178	0.41%	163	0.38%	0	0.00%	108	0.25%	
Arthritis-Rheumatoid																						
#108 DMARD Therapy in Rheumatoid Arthritis	16,913	14,402	85.15%	0	0.00%	0	0.00%	808	4.78%	1,362	8.05%	114	0.67%	84	0.50%	143	0.85%	0	0.00%	61	0.36%	
Asthma																						
#53 Asthma: Pharmacologic Therapy	5,048	303	6.00%	4,705	93.21%	0	0.00%	519	10.28%	672	13.31%	88	1.74%	48	0.95%	8	0.16%	0	0.00%	47	0.93%	
#64 Asthma Assessment	2,912	187	6.42%	2,692	92.45%	0	0.00%	74	2.54%	546	18.75%	55	1.89%	19	0.65%	3	0.10%	0	0.00%	49	1.68%	
Breast Cancer																						
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	62,299	40,668	65.28%	0	0.00%	8,785	14.10%	2,877	4.62%	17,197	27.60%	826	1.33%	555	0.89%	114	0.18%	105	0.17%	289	0.46%	
#74 RT Recommended for Invasive Breast Cancer Patients with Breast Conserving Surgery	9,370	1,713	18.28%	4,743	50.62%	230	2.45%	5,265	56.19%	107	1.14%	626	6.68%	399	4.26%	67	0.72%	0	0.00%	39	0.42%	
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	36,798	19,430	52.80%	0	0.00%	0	0.00%	1,092	2.97%	14,602	39.68%	1,187	3.23%	257	0.70%	230	0.63%	0	0.00%	81	0.22%	
#112 Screening Mammography	59,859	26,035	43.49%	26,113	43.62%	1,414	2.36%	4,090	6.83%	0	0.00%	0	0.00%	6,003	10.03%	0	0.00%	0	0.00%	2,191	3.66%	
Bronchitis																						
#116 Inappropriate Antibiotic Treatment for Adults	280	84	30.00%	167	59.64%	0	0.00%	10	3.57%	100	35.71%	8	2.86%	3	1.07%	1	0.36%	0	0.00%	0	0.00%	
Coronary Artery Bypass Graft (CABG)																						
#43 Use of IMA in CABG Surgery	31,012	19,811	63.88%	0	0.00%	0	0.00%	10,923	35.22%	0	0.00%	0	0.00%	278	0.90%	0	0.00%	0	0.00%	173	0.56%	
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	20,806	12,994	62.45%	0	0.00%	0	0.00%	7,596	36.51%	0	0.00%	0	0.00%	216	1.04%	0	0.00%	0	0.00%	51	0.25%	
CAD																						
#118 ACE or ARB Therapy for Patients with CAD and Diabetes and/or LVSD	43,142	28,592	66.27%	0	0.00%	0	0.00%	1,415	3.28%	7,904	18.32%	434	1.01%	702	1.63%	4,095	9.49%	0	0.00%	37	0.09%	
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	873,519	777,940	89.06%	0	0.00%	0	0.00%	34,136	3.91%	45,348	5.19%	2,713	0.31%	8,545	0.98%	4,837	0.55%	0	0.00%	1,706	0.20%	
#7 Beta-blocker Therapy for CAD Patients with Prior MI	284,705	92,186	32.38%	0	0.00%	0	0.00%	4,092	1.44%	176,409	61.96%	9,239	3.25%	1,053	0.37%	1,726	0.61%	0	0.00%	655	0.23%	
Chemotherapy																						
#73 Plan Documented Before Chemotherapy Administered	23,830	6,366	26.71%	0	0.00%	0	0.00%	7,544	31.66%	4,222	17.72%	5,171	21.70%	403	1.69%	124	0.52%	0	0.00%	27	0.11%	

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.
^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.
^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.
^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.
^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.
^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.
^h The # of occurrences where a valid NPI is not present.

Note: MCMP and GGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).

Measure	QDC Submission Attempts			Denominator Mismatch ^c														Resubmitted QDCs ^f		Unattributed (No NPI) ^g					
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC									
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%						
Chest Pain																									
#54 ECG Performed for Non-Traumatic Chest Pain	841,973	600,431	71.31%	11,491	1.36%	0	0.00%	27,852	3.31%	191,055	22.69%	8,667	1.03%	3,859	0.46%	1,316	0.16%	0	0.00%	9,007	1.07%				
Chronic Kidney Disease (CKD)																									
#120 ACE Inhibitor or ARB Therapy in Patients with CKD	6,774	571	8.43%	0	0.00%	0	0.00%	1	0.01%	5,446	80.40%	482	7.12%	0	0.00%	274	4.04%	0	0.00%	0	0.00%				
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	4,143	3,272	78.98%	0	0.00%	0	0.00%	121	2.92%	386	9.32%	261	6.30%	14	0.34%	89	2.15%	0	0.00%	0	0.00%				
#122 Blood Pressure Management	30,083	27,317	90.81%	0	0.00%	0	0.00%	636	2.11%	1,794	5.96%	260	0.86%	37	0.12%	39	0.13%	0	0.00%	0	0.00%				
#123 Plan of Care: Elevated Hemoglobin for Patients Receiving ESAs	138,573	8,224	5.93%	17	0.01%	0	0.00%	956	0.69%	761	0.55%	14,029	10.12%	78	0.06%	114,525	82.65%	0	0.00%	1	0.00%				
Colon Cancer																									
#72 Chemotherapy for Stage III Colorectal Cancer (CRC)	39,811	10,965	27.54%	0	0.00%	0	0.00%	775	1.95%	26,404	66.32%	1,260	3.16%	114	0.29%	259	0.65%	88	0.22%	193	0.48%				
#100 CRC Patients with a pT and pN Category and Histologic Grade	35,282	13,388	37.95%	0	0.00%	0	0.00%	835	2.37%	4,430	12.56%	15,405	43.66%	220	0.62%	1,004	2.85%	0	0.00%	79	0.22%				
#113 CRC Screening	126,962	87,271	68.74%	22,726	17.90%	0	0.00%	5,120	4.03%	0	0.00%	0	0.00%	13,069	10.29%	0	0.00%	0	0.00%	359	0.28%				
Chronic Obstructive Pulmonary Disease (COPD)																									
#51 Spirometry Evaluation	70,286	60,683	86.34%	0	0.00%	0	0.00%	2,665	3.79%	5,501	7.83%	455	0.65%	709	1.01%	263	0.37%	0	0.00%	307	0.44%				
#52 Bronchodilator Therapy	61,209	53,357	87.17%	0	0.00%	0	0.00%	2,231	3.64%	4,387	7.17%	315	0.51%	649	1.06%	261	0.43%	0	0.00%	175	0.29%				
Catheter-Related Bloodstream Infections (CRBSI)																									
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	36,316	32,144	88.51%	0	0.00%	0	0.00%	3,682	10.14%	0	0.00%	0	0.00%	490	1.35%	0	0.00%	0	0.00%	125	0.34%				
Depression																									
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of MD	12,159	6,500	53.46%	0	0.00%	0	0.00%	1,276	10.49%	3,130	25.74%	1,086	8.93%	105	0.86%	62	0.51%	0	0.00%	93	0.76%				
#106 Patients who have MD Disorder who meet DSM IV Criteria	2,894	2,090	72.22%	0	0.00%	0	0.00%	408	14.10%	312	10.78%	24	0.83%	45	1.55%	15	0.52%	0	0.00%	0	0.00%				
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	6,648	5,408	81.35%	0	0.00%	0	0.00%	473	7.11%	629	9.46%	26	0.39%	93	1.40%	19	0.29%	0	0.00%	0	0.00%				
Diabetes																									
#1 Hemoglobin A1c Poor Control	520,323	301,228	57.89%	167,581	32.21%	0	0.00%	26,743	5.14%	25,496	4.90%	2,186	0.42%	9,744	1.87%	2,336	0.45%	0	0.00%	3,744	0.72%				
#2 Low Density Lipoprotein Control	484,901	282,370	58.23%	155,158	32.00%	0	0.00%	24,942	5.14%	27,701	5.71%	1,808	0.37%	8,316	1.71%	1,196	0.25%	0	0.00%	3,629	0.75%				
#3 High Blood Pressure Control	539,562	293,416	54.38%	178,011	32.99%	0	0.00%	26,546	4.92%	52,717	9.77%	3,772	0.70%	10,445	1.94%	4,022	0.75%	0	0.00%	3,880	0.72%				

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.
^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.
^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.
^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.
^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.
^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.
^h The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).

Measure	QDC Submission Attempts			Denominator Mismatch ^e														Resubmitted QDCs ^f		Unattributed (No NPI) ^g		
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC						
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%			
Diabetes																						
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	219,460	165,820	75.56%	0	0.00%	0	0.00%	9,130	4.16%	39,751	18.11%	2,562	1.17%	1,625	0.74%	512	0.23%	0	0.00%	1,456	0.66%	
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	161,216	114,217	70.85%	0	0.00%	0	0.00%	5,856	3.63%	38,384	23.81%	1,224	0.76%	1,170	0.73%	325	0.20%	0	0.00%	1,122	0.70%	
#117 Dilated Eye Exam in Diabetic Patient	246,618	143,248	58.08%	90,816	36.82%	0	0.00%	8,042	3.26%	7,405	3.00%	557	0.23%	2,791	1.13%	108	0.04%	0	0.00%	913	0.37%	
#119 Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	191,847	17,591	9.17%	98,496	51.34%	0	0.00%	3,519	1.83%	136,910	71.36%	17,737	9.25%	2,735	1.43%	2,524	1.32%	0	0.00%	432	0.23%	
#126 Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation	24,801	19,621	79.11%	0	0.00%	0	0.00%	1,186	4.78%	2,158	8.70%	181	0.73%	1,491	6.01%	164	0.66%	0	0.00%	14	0.06%	
#127 Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear	9,934	7,447	74.96%	0	0.00%	0	0.00%	384	3.87%	1,296	13.05%	107	1.08%	608	6.12%	92	0.93%	0	0.00%	5	0.05%	
End Stage Renal Disease (ESRD)																						
#78 Vascular Access for Patients Undergoing Hemodialysis	23,807	21,347	89.67%	3	0.01%	0	0.00%	179	0.75%	327	1.37%	87	0.37%	1,818	7.64%	49	0.21%	0	0.00%	0	0.00%	
#79 Influenza Vaccination in Patients with ESRD	16,741	12,508	74.71%	1	0.01%	0	0.00%	102	0.61%	96	0.57%	3,223	19.25%	726	4.34%	86	0.51%	0	0.00%	40	0.24%	
#80 Plan of Care for ESRD Patients with Anemia	130,412	120,193	92.16%	17	0.01%	0	0.00%	300	0.23%	254	0.19%	6,202	4.76%	3,275	2.51%	186	0.14%	0	0.00%	1	0.00%	
#81 Plan of Care for Inadequate Hemodialysis	111,953	103,241	92.22%	25	0.02%	0	0.00%	718	0.64%	140	0.13%	115	0.10%	7,612	6.80%	122	0.11%	0	0.00%	5	0.00%	
#82 Plan of Care for Inadequate Peritoneal Dialysis	113,531	3,323	2.93%	25	0.02%	0	0.00%	9,365	8.25%	10	0.01%	1,988	1.75%	98,242	86.53%	598	0.53%	0	0.00%	5	0.00%	
Falls																						
#4 Screening for Future Fall Risk	459,469	371,498	80.85%	37,381	8.14%	0	0.00%	44,912	9.77%	0	0.00%	0	0.00%	10,002	2.18%	0	0.00%	2	0.00%	5,287	1.15%	
GERD																						
#77 Assessment of GERD Symptoms in Patients Receiving Chronic Medication for GERD	21,147	15,191	71.84%	0	0.00%	0	0.00%	582	2.75%	4,753	22.48%	406	1.92%	177	0.84%	38	0.18%	0	0.00%	18	0.09%	
Glaucoma																						
#12 Optic Nerve Evaluation	730,139	649,926	89.01%	1	0.00%	0	0.00%	25,893	3.55%	44,612	6.11%	2,897	0.40%	5,855	0.80%	587	0.08%	0	0.00%	5,194	0.71%	

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.

^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.

^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.

^h The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Measure	QDC Submission Attempts			Denominator Mismatch ^e														Resubmitted QDCs ^f		Unattributed (No NPI) ^g	
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC					
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
Heart Failure																					
#5 ACE Inhibitor or ARB Therapy for LVSD	226,047	155,515	68.80%	0	0.00%	0	0.00%	9,534	4.22%	51,289	22.69%	3,136	1.39%	3,335	1.48%	3,238	1.43%	0	0.00%	497	0.22%
#8 Beta-blocker Therapy for LVSD	122,511	96,182	78.51%	0	0.00%	0	0.00%	7,844	6.40%	14,081	11.49%	823	0.67%	1,648	1.35%	1,933	1.58%	0	0.00%	139	0.11%
Hepatitis C (HCV)																					
#83 Testing of Patients with Chronic HCV for Hepatitis C Viremia	1,159	1,003	86.54%	0	0.00%	0	0.00%	44	3.80%	66	5.69%	2	0.17%	44	3.80%	0	0.00%	0	0.00%	0	0.00%
#84 Initial Hepatitis C RNA Testing	1,196	1,023	85.54%	0	0.00%	0	0.00%	36	3.01%	73	6.10%	21	1.76%	41	3.43%	2	0.17%	0	0.00%	0	0.00%
#85 Genotype Testing Prior to Therapy	1,453	1,213	83.48%	0	0.00%	0	0.00%	39	2.68%	135	9.29%	21	1.45%	43	2.96%	2	0.14%	0	0.00%	0	0.00%
#86 Consideration for Antiviral Therapy	943	817	86.64%	0	0.00%	0	0.00%	32	3.39%	42	4.45%	11	1.17%	40	4.24%	1	0.11%	0	0.00%	0	0.00%
#87 RNA Testing at Week 12 of Therapy	431	291	67.52%	0	0.00%	0	0.00%	12	2.78%	78	18.10%	10	2.32%	40	9.28%	0	0.00%	0	0.00%	0	0.00%
#88 Hepatitis A and B Vaccination	827	731	88.39%	0	0.00%	0	0.00%	30	3.63%	31	3.75%	3	0.36%	32	3.87%	0	0.00%	0	0.00%	0	0.00%
#89 Counseling Patients Regarding Use of Alcohol	603	496	82.26%	0	0.00%	0	0.00%	22	3.65%	50	8.29%	0	0.00%	35	5.80%	0	0.00%	0	0.00%	0	0.00%
#90 Counseling Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy	213	104	48.83%	75	35.21%	0	0.00%	7	3.29%	36	16.90%	1	0.47%	24	11.27%	1	0.47%	0	0.00%	0	0.00%
HIT																					
#124 HIT - Adoption/Use of EHRs	1,602,395	1,485,648	92.71%	11	0.00%	0	0.00%	89,314	5.57%	0	0.00%	0	0.00%	27,425	1.71%	0	0.00%	0	0.00%	1,996	0.12%
#125 HIT - Adoption/Use of e-Prescribing	231,411	218,754	94.53%	0	0.00%	0	0.00%	10,615	4.59%	0	0.00%	0	0.00%	2,042	0.88%	0	0.00%	0	0.00%	505	0.22%
Imaging-Stroke																					
#10 CT or MRI Reports	156,583	140,914	89.99%	0	0.00%	0	0.00%	4,785	3.06%	8,885	5.67%	683	0.44%	1,263	0.81%	53	0.03%	0	0.00%	346	0.22%
#11 Carotid Imaging Reports	45,100	35,915	79.63%	0	0.00%	0	0.00%	1,986	4.40%	4,148	9.20%	2,348	5.21%	447	0.99%	256	0.57%	0	0.00%	139	0.31%
Influenza																					
#110 Vaccination for Patients ≥ 50 Years Old	129,970	103,348	79.52%	1,298	1.00%	0	0.00%	6,654	5.12%	0	0.00%	0	0.00%	18,791	14.46%	0	0.00%	0	0.00%	816	0.63%
#129 Universal Vaccine Screening and Counseling	22,766	13,425	58.97%	386	1.70%	0	0.00%	6,148	27.01%	0	0.00%	0	0.00%	2,878	12.64%	0	0.00%	0	0.00%	0	0.00%
Leukemia (CLL)																					
#70 Baseline Flow Cytometry	10,404	8,853	85.09%	0	0.00%	0	0.00%	498	4.79%	913	8.78%	25	0.24%	104	1.00%	11	0.11%	0	0.00%	4	0.04%
Macular Degeneration																					
#14 Dilated Macular Examination	555,026	509,983	91.88%	638	0.11%	0	0.00%	22,493	4.05%	17,745	3.20%	1,031	0.19%	2,851	0.51%	188	0.03%	0	0.00%	3,391	0.61%
Myelodysplastic Syndrome (MDS) and Acute Leukemias																					
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	11,699	9,071	77.54%	0	0.00%	0	0.00%	870	7.44%	1,478	12.63%	48	0.41%	213	1.82%	19	0.16%	0	0.00%	11	0.09%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	9,209	7,538	81.85%	0	0.00%	0	0.00%	559	6.07%	991	10.76%	23	0.25%	93	1.01%	5	0.05%	0	0.00%	11	0.12%

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.

^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.

^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.

^h The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Measure	QDC Submission Attempts			Denominator Mismatch ^e														Resubmitted QDCs ^f		Unattributed (No NPI) ^g	
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC					
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%		
Medication Management																					
#46 Medication Reconciliation	62,534	15,963	25.53%	3,262	0.00%	0	0.00%	44,038	70.42%	0	0.00%	0	0.00%	1,408	2.25%	0	0.00%	0	0.00%	25	0.04%
#130 Documentation of Current Medications	157,637	52,165	33.09%	1	0.00%	0	0.00%	98,103	62.23%	0	0.00%	0	0.00%	7,369	4.67%	0	0.00%	0	0.00%	110	0.07%
Mental Health																					
#133 Screening for Cognitive Impairment	7,861	4,153	52.83%	656	8.34%	0	0.00%	1,987	25.28%	0	0.00%	0	0.00%	1,384	17.61%	0	0.00%	0	0.00%	0	0.00%
#134 Screening for Clinical Depression	4,964	3,002	60.48%	0	0.00%	0	0.00%	1,542	31.06%	0	0.00%	0	0.00%	420	8.46%	0	0.00%	0	0.00%	0	0.00%
Myeloma																					
#69 Treatment with Bisphosphonates	8,026	6,804	84.77%	0	0.00%	0	0.00%	525	6.54%	523	6.52%	45	0.56%	124	1.54%	5	0.06%	0	0.00%	51	0.64%
Myocardial Infarction																					
#28 Aspirin at Arrival	33,210	28,343	85.34%	0	0.00%	0	0.00%	1,226	3.69%	3,263	9.83%	179	0.54%	174	0.52%	25	0.08%	0	0.00%	120	0.36%
Obesity																					
#128 Universal Weight Screening and Follow-Up	75,797	54,430	71.81%	5,501	7.26%	0	0.00%	3,780	4.99%	0	0.00%	0	0.00%	12,585	16.60%	0	0.00%	0	0.00%	11	0.01%
Osteoporosis																					
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	9,564	4,895	51.18%	78	0.82%	0	0.00%	630	6.59%	2,715	28.39%	517	5.41%	213	2.23%	577	6.03%	0	0.00%	6	0.06%
#39 Screening or Therapy for Women Aged 65 Years and Older	190,248	155,016	81.48%	5,489	2.89%	4,723	2.48%	14,464	7.60%	0	0.00%	0	0.00%	12,043	6.33%	0	0.00%	0	0.00%	100	0.05%
#40 Management Following Fracture	232,377	3,558	1.53%	1,463	0.63%	0	0.00%	498	0.21%	213,713	91.97%	10,280	4.42%	186	0.08%	4,133	1.78%	0	0.00%	3,589	1.54%
#41 Pharmacologic Therapy	111,020	48,760	43.92%	693	0.62%	0	0.00%	1,896	1.71%	54,184	48.81%	3,633	3.27%	572	0.52%	1,706	1.54%	1	0.00%	1,958	1.76%
Otitis																					
#91 AOE: Topical Therapy	871	769	88.29%	0	0.00%	0	0.00%	33	3.79%	52	5.97%	1	0.11%	16	1.84%	0	0.00%	0	0.00%	2	0.23%
#92 AOE: Pain Assessment	1,176	1,040	88.44%	0	0.00%	0	0.00%	33	2.81%	76	6.46%	2	0.17%	25	2.13%	0	0.00%	0	0.00%	2	0.17%
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	815	716	87.85%	0	0.00%	0	0.00%	26	3.19%	49	6.01%	1	0.12%	23	2.82%	0	0.00%	0	0.00%	2	0.25%
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	2,315	0	0.00%	2,315	100.00%	0	0.00%	1	0.04%	1,950	84.23%	309	13.35%	0	0.00%	2	0.09%	0	0.00%	0	0.00%
#95 OME: Hearing Testing	5	0	0.00%	5	100.00%	0	0.00%	1	20.00%	1	20.00%	2	40.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
#96 OME: Antihistamines or Decongestants – Avoidance of Inappropriate Use	4	0	0.00%	4	100.00%	0	0.00%	0	0.00%	2	50.00%	1	25.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%
#97 OME: Systemic Antimicrobials – Avoidance of Inappropriate Use	935	0	0.00%	935	100.00%	0	0.00%	1	0.11%	878	93.90%	26	2.78%	0	0.00%	23	2.46%	0	0.00%	2	0.21%
#98 OME: Systemic Corticosteroids – Avoidance of Inappropriate Use	5	0	0.00%	5	100.00%	0	0.00%	0	0.00%	1	20.00%	1	20.00%	0	0.00%	0	0.00%	0	0.00%	0	0.00%

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.

^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.

^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.

^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.

^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.

^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.

^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.

^h The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Measure	QDC Submission Attempts			Denominator Mismatch ^e														Resubmitted QDCs ^f		Unattributed (No NPI) ^g		
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC						
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%			
Pain Management																						
#131 Assessment Prior to Initiation of Patient Treatment	188,514	177,386	94.10%	0	0.00%	0	0.00%	8,641	4.58%	0	0.00%	0	0.00%	2,481	1.32%	0	0.00%	0	0.00%	216	0.11%	
Perioperative																						
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	1,168,641	156,784	13.42%	131	0.01%	0	0.00%	986,363	84.40%	0	0.00%	0	0.00%	25,474	2.18%	0	0.00%	1	0.00%	4,313	0.37%	
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	143,508	116,338	81.07%	22	0.02%	0	0.00%	25,786	17.97%	0	0.00%	0	0.00%	1,377	0.96%	0	0.00%	1	0.00%	419	0.29%	
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	133,263	87,311	65.52%	11	0.01%	0	0.00%	44,338	33.27%	0	0.00%	0	0.00%	1,611	1.21%	0	0.00%	0	0.00%	552	0.41%	
#23 VTE Prophylaxis	95,940	71,563	74.59%	17	0.02%	0	0.00%	23,027	24.00%	0	0.00%	0	0.00%	1,350	1.41%	0	0.00%	1	0.00%	309	0.32%	
#30 Timing of Prophylactic Antibiotics - Administering Physician	1,010,634	905,863	89.63%	115	0.01%	0	0.00%	101,849	10.08%	0	0.00%	0	0.00%	2,922	0.29%	0	0.00%	1	0.00%	3,601	0.36%	
#45 Discontinuation of Prophylactic Antibiotics	131,488	55,516	42.22%	7	0.01%	0	0.00%	72,760	55.34%	0	0.00%	0	0.00%	3,212	2.44%	0	0.00%	0	0.00%	608	0.46%	
Pharyngitis																						
#66 Appropriate Testing for Children Plan of Care	303	0	0.00%	303	100.00%	0	0.00%	2	0.66%	250	82.51%	30	9.90%	0	0.00%	4	1.32%	0	0.00%	0	0.00%	
#132 Patient Co-Development of Treatment Plan	69,767	61,923	88.76%	0	0.00%	0	0.00%	4,889	7.01%	0	0.00%	0	0.00%	2,955	4.24%	0	0.00%	0	0.00%	86	0.12%	
Pneumonia																						
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	280,868	263,078	93.67%	4	0.00%	0	0.00%	9,545	3.40%	6,084	2.17%	700	0.25%	1,367	0.49%	91	0.03%	0	0.00%	1,444	0.51%	
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	334,790	305,460	91.24%	5	0.00%	0	0.00%	11,938	3.57%	13,959	4.17%	835	0.25%	1,979	0.59%	615	0.18%	0	0.00%	3,671	1.10%	
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	269,929	255,156	94.53%	4	0.00%	0	0.00%	10,137	3.76%	2,835	1.05%	227	0.08%	1,540	0.57%	30	0.01%	0	0.00%	3,530	1.31%	
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	182,783	173,228	94.77%	3	0.00%	0	0.00%	6,567	3.59%	1,798	0.98%	268	0.15%	889	0.49%	30	0.02%	0	0.00%	1,288	0.70%	
#75 Prevention of Ventilator-Associated Pneumonia - Head Elevation	2,668	2,295	86.02%	0	0.00%	0	0.00%	367	13.76%	0	0.00%	0	0.00%	6	0.22%	0	0.00%	0	0.00%	38	1.42%	
Pneumonia Pneumococcal																						
#111 Vaccination for Patients 65 years and Older	212,371	178,074	83.85%	8,971	4.22%	0	0.00%	11,317	5.33%	0	0.00%	0	0.00%	14,683	6.91%	0	0.00%	0	0.00%	1,075	0.51%	

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.
^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.
^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.
^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.
^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.
^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.
^h The # of occurrences where a valid NPI is not present.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Measure	QDC Submission Attempts			Denominator Mismatch ^e														Resubmitted QDCs ^f		Unattributed (No NPI) ^g		
	Total QDCs Reported ^a	Total Valid QDCs Reported ^b	% Valid	Patient Age Mismatch ^d		Patient Gender Mismatch ^e		Incorrect HCPCS		Incorrect DX		Both DX and HCPCS Incorrect		Only QDC on Claim		Incorrect DX and Only QDC						
				#	%	#	%	#	%	#	%	#	%	#	%	#	%	#	%			
Prostate Cancer																						
#101 Appropriate Initial Evaluation of Patients with Prostate Cancer	4,788	2,741	57.25%	0	0.00%	0	0.00%	1,466	30.62%	6	0.13%	107	2.23%	374	7.81%	93	1.94%	1	0.02%	3	0.06%	
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	12,669	11,984	94.59%	0	0.00%	0	0.00%	527	4.16%	2	0.02%	44	0.35%	112	0.88%	0	0.00%	0	0.00%	1	0.01%	
#103 Review of Treatment Options in Patients with Clinically Localized Prostate Cancer	3,605	2,032	56.37%	0	0.00%	0	0.00%	1,169	32.43%	9	0.25%	77	2.14%	224	6.21%	92	2.55%	0	0.00%	37	1.03%	
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	1,943	1,494	76.89%	0	0.00%	0	0.00%	355	18.27%	0	0.00%	15	0.77%	79	4.07%	0	0.00%	0	0.00%	1	0.05%	
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	41,012	39,232	95.66%	0	0.00%	0	0.00%	1,127	2.75%	31	0.08%	12	0.03%	587	1.43%	1	0.00%	0	0.00%	649	1.58%	
Stroke and Stroke Rehabilitation																						
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	7,466	4,896	65.58%	0	0.00%	0	0.00%	646	8.65%	1,187	15.90%	588	7.88%	123	1.65%	26	0.35%	0	0.00%	6	0.08%	
#32 Discharged on Antiplatelet Therapy	12,146	9,191	75.67%	0	0.00%	0	0.00%	1,236	10.18%	1,023	8.42%	404	3.33%	267	2.20%	25	0.21%	0	0.00%	40	0.33%	
#33 Anticoagulant Therapy Prescribed for Afib at Discharge	2,965	691	23.31%	0	0.00%	0	0.00%	53	1.79%	1,806	60.91%	310	10.46%	24	0.81%	81	2.73%	0	0.00%	0	0.00%	
#34 t-PA Considered	6,132	3,922	63.96%	0	0.00%	0	0.00%	1,074	17.51%	811	13.23%	203	3.31%	100	1.63%	22	0.36%	0	0.00%	27	0.44%	
#35 Screening for Dysphagia	6,165	3,722	60.37%	0	0.00%	0	0.00%	601	9.75%	961	15.59%	755	12.25%	87	1.41%	39	0.63%	0	0.00%	7	0.11%	
#36 Consideration of Rehabilitation Services	7,470	4,942	66.16%	0	0.00%	0	0.00%	1,147	15.35%	900	12.05%	223	2.99%	202	2.70%	56	0.75%	0	0.00%	25	0.33%	
Syncope																						
#55 ECG Performed for Syncope	841,973	183,290	21.77%	140,391	16.67%	0	0.00%	6,829	0.81%	611,707	72.65%	27,531	3.27%	1,151	0.14%	3,785	0.45%	0	0.00%	9,007	1.07%	
Tobacco Use																						
#114 Inquiry Regarding Tobacco Use	465,561	372,900	80.10%	0	0.00%	0	0.00%	66,177	14.21%	0	0.00%	0	0.00%	26,484	5.69%	0	0.00%	0	0.00%	1,805	0.39%	
#115 Advising Smokers to Quit	272,621	232,537	85.30%	0	0.00%	0	0.00%	21,623	7.93%	0	0.00%	0	0.00%	18,461	6.77%	0	0.00%	0	0.00%	1,142	0.42%	
Upper Respiratory Infection (URI)																						
#65 Appropriate Treatment for Children	281	0	0.00%	281	100.00%	0	0.00%	0	0.00%	223	79.36%	18	6.41%	0	0.00%	4	1.42%	0	0.00%	0	0.00%	
Urinary Incontinence (UI)																						
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	137,713	91,273	66.28%	4,978	3.61%	6,729	4.89%	23,698	17.21%	0	0.00%	0	0.00%	13,863	10.07%	0	0.00%	0	0.00%	3,694	2.68%	
#49 Characterization of UI in Women Aged 65 Years and Older	40,646	24,372	59.96%	1,365	3.36%	708	1.74%	2,579	6.35%	10,312	25.37%	1,820	4.48%	400	0.98%	510	1.25%	0	0.00%	661	1.63%	
#50 Plan of Care for UI in Women Aged 65 Years and Older	37,832	23,533	62.20%	1,218	3.22%	632	1.67%	2,079	5.50%	8,840	23.37%	1,700	4.49%	425	1.12%	392	1.04%	0	0.00%	580	1.53%	
TOTAL	17,444,484	11,913,328	68.29%	997,809	5.72%	23,221	0.13%	2,128,198	12.20%	1,937,996	11.11%	166,981	0.96%	448,412	2.57%	160,658	0.92%	201	0.00%	94,664	0.54%	

^a For each measure, the total # of instances where an NPI/TIN combination submitted a QDC for that measure.
^b For each measure, the # of instances where an NPI/TIN combination submitted a valid QDC for that measure.
^c The # of occurrences of QDC reporting where the QDC does not match the denominator requirements for the measure.
^d The # of occurrences of a QDC reporting where the QDC does not match the age requirements for the measure.
^e The # of occurrences of a QDC reporting where the QDC does not match the gender requirements for the measure.
^f The # of occurrences of a QDC reporting where the QDC was received on a claim that was resubmitted for the purpose of adding QDCs.
^g The total # of occurrences where a QDC was improperly submitted. This is a unique count of report errors based on diagnosis, age, gender and resubmits.
^h The # of occurrences where a valid NPI is not present.

Note: MCMP and GGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).